How to think about stacking Selank
- Selank is a stabilised tuftsin analog. Its reported anxiolysis without sedation or dependence is the specific contrast with benzodiazepines that the literature emphasises.
- N-Acetyl Selank Amidate is the same molecule stabilised. Combining them is a duplicate.
- Published research is predominantly intranasal, and the registered Russian product is an intranasal solution.
- No controlled trial has studied Selank combined with anything.
Combinations in detail
Russian nootropic pairing
Selank + Semax- Why it is proposed
- Complementary framings from the same research tradition — anxiolysis alongside attention and neuroprotection, through different proposed mechanisms.
- What is reported in practice
- Reported intranasally, commonly on the same day with Semax earlier and Selank later.
- Cautions specific to this combination
- Shared literature concentration; no independent replication at scale for either component or the pair.
Sleep and stress discussion
Selank + DSIP- Why it is proposed
- Reported as pairing daytime anxiolysis with a sleep-oriented peptide.
- What is reported in practice
- Selank during the day, DSIP at night.
- Cautions specific to this combination
- DSIP's evidence base is very thin and its reported effects inconsistent. The rationale is scheduling rather than mechanism.
Mood and anxiety discussion
Selank + Oxytocin- Why it is proposed
- Both are discussed in social and anxiety contexts through unrelated mechanisms — tuftsin-derived monoamine modulation versus oxytocin-receptor signaling.
- What is reported in practice
- Both reported intranasally, which at least matches both evidence bases.
- Cautions specific to this combination
- The intranasal oxytocin behavioural literature has documented replication failures. Combining two compounds with contested behavioural literatures compounds that uncertainty.
What to avoid, and why
- Combining Selank with N-Acetyl Selank Amidate — same compound, two forms.
- Substituting it for prescribed anxiety treatment on the basis of the no-dependence framing; that framing comes from a thin literature and is not a clinical equivalence claim.
- Assuming injection matches the evidence; the registered product and most research are intranasal.
- This compound's evidence base is concentrated in Russian-language literature from a small number of research groups, with limited independent Western replication, and the published research is predominantly intranasal rather than injected. Both facts should temper how confidently any stack built on it is read.
Related reading
Every combination described here is reported practice or mechanism-level reasoning. No controlled trial has studied any of these combinations, and nothing on this page is a personal protocol, a dose recommendation, or medical advice.